Hoth Therapeutics Announces Issuance of Chinese Patent for Cancer Cell-Targeting Technology

Core Viewpoint - Hoth Therapeutics has been granted a Chinese patent for its cancer cell-targeting technology, which enhances its intellectual property portfolio and provides protection in a significant global market until August 27, 2039 [1][3]. Group 1: Patent Details - The patent is titled "Targeting Kit with Splice Switching Oligonucleotides to Induce Apoptosis of Mast Cells" and relates to a therapeutic platform that selectively induces apoptosis in mast cells, which are involved in various inflammatory and immunological conditions [2][1]. - The patent was originally filed under PCT Application No. PCT/US2019/048400 and was developed in collaboration with North Carolina State University [1]. Group 2: Company Perspective - The CEO of Hoth Therapeutics, Robb Knie, emphasized that the patent grant in China is a significant milestone for expanding global intellectual property protection and believes the technology has broad potential across multiple indications related to mast cell activity [3]. - Hoth Therapeutics is focused on developing innovative therapies aimed at unmet medical needs, utilizing a patient-centric approach and collaborating with scientists and clinicians to advance drug development [4].